Clover Health Is Down Big. Is It a Buy?
Chamath Palihapitiya has taken three companies public through his special-purpose acquisition companies (SPACs) and has announced a fourth in recent months. Since their merger announcements, all are handily outperforming the market but one -- Clover Health (NASDAQ: CLOV). In this Fool Live video clip, recorded on March 15, Fool.com contributors Matt Frankel, CFP, Brian Withers, and Dan Caplinger discuss why Clover Health has performed so poorly and whether the stock is worth a look for long-term investors now.
Source Fool.com